USFDA issues EIR for Granules India’s Gagillapur facility in Hyderabad

13 Jul 2023 Evaluate

US Food & Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Granules India’s Gagillapur facility located in Hyderabad, Telangana, India. This facility, that manufacturers finished dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs) was inspected by the USFDA as a part of a PAI in January 2023 which resulted in 3 observations during the inspection. 

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

576.80 3.00 (0.52%)
06-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1798.95
Dr. Reddys Lab 1303.90
Cipla 1321.75
Zydus Lifesciences 912.95
Lupin 2344.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×